EU MDR vs FDA Pathway for OEM Menstrual Cups — Regulatory Roadmap for Multi-Market Brands

Multi-market OEM brands routinely ask: “If our factory is ISO 13485 and FDA registered, are we CE-ready and Amazon-safe?” The honest answer is partially — shared manufacturing evidence accelerates both pathways, but EU MDR and US general controls assign different obligations to manufacturers, importers, and brand owners. Treating a factory certificate as a universal passport is how listings go live in September and stall in November under document requests.

This roadmap is for regulatory affairs leads, founders, and distributors planning EU + US + UK placement of menstrual cups and discs manufactured at Xi’an Furuize Biotechnology Co., Ltd. or comparable OEMs. Deep dives live on CE, FDA, ISO 13485, and SGS pages — here we compare pathways, timelines, and ownership.

Device Classification Snapshot

Most reusable silicone cups/discs are not implantables or life-sustaining — but they are regulated devices, not generic consumer goods.

Role Split — Who Owns What

Blurry roles cause the most delays — contract clarity beats hurry.

Video: Regulatory Document Map

Furuize YouTube channel — manufacturing compliance context
Use alongside downloadable indexes from your account manager during NDA onboarding.

EU MDR Pathway — OEM Timeline Model

Indicative new brand / new mold timeline with competent regulatory consultant:

Accelerators: Catalog mold with existing Furuize technical file supplements; literature-based clinical evaluation for established geometry.

Delays: New pigment without chemical reassessment; missing AR appointment; IFU claims exceeding test evidence.

See CE certification page for GSPR and technical file structure — not duplicated here.

FDA General Controls Pathway — OEM Timeline Model

Critical language: “FDA registered manufacturing facility” ≠ “FDA approved cup.” Misleading copy triggers marketplace takedowns.

Detail on establishment registration: FDA page.

Side-by-Side Evidence Reuse Matrix

One test, two files — index reports once in manufacturer DMR; brand regulatory lead forks regional cover sheets.

Cost Budget Illustration (Planning Only)

USD bands vary by NB and SKU complexity — use as board-level reserves, not quotes.

UKCA Post-Brexit Note

Great Britain requires UKCA conformity and UK Responsible Person for many device routes. EU CE alone does not clear GB after transitional rules evolve. Dual-file brands maintain:

• EU: CE + AR + EUDAMED
• UK: UKCA + UKRP + MHRA registration steps

Factory technical files at Furuize support both with regional cover pages — plan three indexes (EU/US/UK) off one DMR core.

Common Filing Mistakes (OEM Brands)

Regulatory Gantt — Dual Market Launch (ASCII)

Month:  1    2    3    4    5    6    7    8    9
EU TF:  [==========]
NB:              [============]
EU ship:                              *
US file:[======]
US ship:                    *

Run US operational launch when factory evidence complete even if EU NB still in review — if US entity and listings ready. Do not ship EU until CE chain closed.

Working With Factory on Multi-Market Files

Furuize deliverables for dual-path brands:

1. DMR index per SKU with mold and material IDs
2. Sanitized Annex II table of contents for EU consultant
3. FDA establishment verification letter
4. SGS report index with refresh dates
5. Change-control notification template for pigment/mold events
6. Post-market complaint routing SOP draft

Your consultant remains legal manufacturer strategist on Declarations and listings — factory does not replace importer vigilance duties.

Clinical Evaluation and Performance File — EU vs US Depth

EU MDR expects a Clinical Evaluation Report (CER) even for well-established cup geometries — often literature-based for mature designs, but the benefit–risk conclusion must be explicit and signed. US general controls rarely demand a CER-shaped document in the same form, yet Amazon and retail reviewers increasingly ask for performance narrative tying capacity claims and material safety to test reports.

Brands launching both markets should task their EU consultant to produce CER content that US packaging teams can excerpt — avoiding duplicate medical writing fees. Factory mechanical verification data from testing lab protocols feeds both files when test method IDs are harmonized.

Labeling and Claims — Regional Copy Control

Maintain a claims matrix spreadsheet approved by regulatory before design ships retail boxes — packaging revs are the fastest way to invalidate a technical file.

Selecting Regulatory Consultants and Notified Bodies

OEM brands should interview advisors with menstrual device experience, not general consumer goods certifiers:

• Ask for redacted Class IIa intimate device timelines they led in the last 24 months.
• Confirm NB quotes include surveillance audit years three through five — not only initial cert fee.
• US counsel should understand general controls without defaulting to 510(k) budget when exempt rationales apply.
• Factory participates in TF workshops but does not ghost-write Declarations on brand letterhead.

Furuize supplies technical appendices; brand counsel owns legal signatory decisions.

Decision Tree — Which Market First?

Post-Market Surveillance — Dual-File Operating Rhythm

After launch, synchronize EU PSUR inputs and US complaint trending monthly:

Brands that treat post-market as one dataset, two reports spend less than brands rebuilding evidence after a serious complaint.

Schedule a regulatory readiness workshop with factory QA before any crowdfunding or pharmacy LOI announcement — public launch dates without closed NB contracts are a leading cause of EU shipment slips that damage brand credibility in trade press. Treat regulatory budget as CAPEX alongside molds, not as a post-launch administrative surprise.

Conclusion

EU MDR and FDA pathways share manufacturing DNA but diverge on legal actors, timelines, and labeling grammar. OEM brands win by indexing evidence once, regionalizing claims twice, and sequencing certificates before cartons print. Use factory ISO and SGS depth as acceleration — not as a substitute for notified-body certificates or importer registrations.

Next in series: marketplace and pharmacy vendor compliance — operationalizing these files at Amazon and retail gates. Request regulatory onboarding via contact or solutions.